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Abstract
Background: The Proteasix Ontology (PxO) is an ontology that supports the Proteasix tool; an open-source
peptide-centric tool that can be used to predict automatically and in a large-scale fashion in silico the proteases
involved in the generation of proteolytic cleavage fragments (peptides)
Methods: The PxO re-uses parts of the Protein Ontology, the three Gene Ontology sub-ontologies, the Chemical
Entities of Biological Interest Ontology, the Sequence Ontology and bespoke extensions to the PxO in support of a
series of roles: 1. To describe the known proteases and their target cleaveage sites. 2. To enable the description of
proteolytic cleaveage fragments as the outputs of observed and predicted proteolysis. 3. To use knowledge about the
function, species and cellular location of a protease and protein substrate to support the prioritisation of proteases in
observed and predicted proteolysis.
Results: The PxO is designed to describe the biological underpinnings of the generation of peptides. The
peptide-centric PxO seeks to support the Proteasix tool by separating domain knowledge from the operational
knowledge used in protease prediction by Proteasix and to support the confirmation of its analyses and results.
Availability: The Proteasix Ontology may be found at: http://bioportal.bioontology.org/ontologies/PXO. This
ontology is free and open for use by everyone.
Keywords: Ontology, Proteasix, Protease prediction, Peptide, Cleaveage site, Open biomedical ontologies
Background
Proteases are enzymes that catalyze peptide bond cleav-
age and this activity can lead to the generation of protein
cleavage fragments or peptides. Proteases have a wide
spectrum of specificity [1]. The human genome encodes
over 550 different proteases, participating in many dif-
ferent biological processes, including protein degradation,
immunity response, regeneration or cell division and are
involved in diseases such as cancer, inflammation and
cardiovascular disease [2, 3].
Body fluids (e.g. serum, urine, cerebrospinal fluid)
contain thousands of protein fragments and disease-
associated peptides. The proteolyticmechanisms that lead
to the generation of these fragments may be associated
with diseases, and are not well described in the literature.
Further insight into the proteases implicated in peptide
generation may help in understanding some diseases.
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The particular function and specificity of each protease
are defined by their binding to a characteristic amino
acid motif that forms a cleavage site in the protein tar-
get [4]. Knowledge about proteases and their substrates
and cleavage sites is scattered across publications and
databases. These different resources do not permit cleav-
age site information to be retrieved from peptide sequence
input automatically and thus elucidating the proteases
implied in peptide production is difficult.
The Proteasix tool [5, 6], is an open-source peptide-
centric tool that can be used to predict automatically the
proteases involved in the generation of proteolytic cleav-
age fragments (peptides). Proteasix is a tool that uses
protease/cleavage sites (CS) associations established by
either observations or predictions to suggest the proteases
implicated in the generation of a peptide. Proteasix does
this by using the N- and C-terminal sequences of pep-
tides that are reconstructed using information from the
UniProt knowledge base [7] to identify the possible pro-
teases that were involved in their generation [5]. Obser-
vations of protease/CS combinations were extracted from
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CutDB [8], UniProt and the literature. When a previous
observation has not been established, Proteasix calcu-
lates the probability of protease/CS association by using
the MEROPS [9] and BRENDA [10] databases. Pro-
teases exhibit varying binding affinities for amino-acid
sequences, ranging from strict restriction to one or few
critical amino-acids in given positions, to generic bind-
ing with little discrimination between different amino
acids [5].
The predictions currently made by Proteasix are agnos-
tic as to the taxon of the organism whence the peptides
come, the cellular location of the predicted proteases and
the proteins theymay cleave. Also, the function of the pro-
teases, e.g., whether they are an endo- or exo-peptidase
is not taken into account. This is the kind of knowledge
an ontology is able to provide. Thus the new version of
Proteasix uses the Proteasix Ontology (PxO) to make this
knowledge available to its algorithm.We go on to describe
the PxO and its role in Proteasix.
Competency questions for the PxO
The PxO is written in theWebOntology Language (OWL)
[11] using the Protégé [12] version 5.0.0 beta 17 editor.
In creating PxO we wished to undertake as little de novo
ontology development as possible and to take advantage
of the work already done in annotating gene products with
the Gene Ontology (GO) [13]. This implied a strategy of
re-using relevant Open biomedical Ontologies Consor-
tium [14] (OBO) ontologies where possible, together with
relevant annotations. The choice of which of the OBO to
use was driven by a set of competency questions (CQ)
that the PxO should fulfil. Once chosen, relevant por-
tions of the ontologies were taken and extended in a way
that accommodated the CQ, making appropriate commit-
ments to the ontology used. The resulting PxO was then
evaluated against the CQ.
To obtain the observed and predicted proteases respon-
sible for the generation of peptides, the PxO needs to
answer the following CQ:
1. What are the known protease and their target cleav-
age sites (observed and/or predicted)?
2. For a given peptide and protein from which it was
derived, what are the cleavage sites that led to its pro-
duction and is it the product of observed or predicted
proteolysis?
3. What are the function, species and cellular location
for both proteases and their substrate proteins?
4. For a given protease, what are its cleavage site speci-
ficity?
5. Given an amino acid, what are its biochemical prop-
erties?
6. For a protease predicted to have generated a peptide,
what are its function and the processes in which it is
known to participate?
The Additional file 1 provides the ELK reasoner times
and shows the SPARQL SELECT queries for the CQ
and the execution times for the CQ using JENA
ARQ [15].
Reuse of ontologies fromOBO
To enable these competencies to be answered the PxO re-
uses parts of some of the OBO; PxO uses the OWL [11]
versions. After downloading the OWL files, a selection
of class names (without deprecated classes); class expres-
sions; class definitions; and annotation assertions were
extracted. Where only a portion of the source ontology
was required to support the CQ in PxO, we program-
matically extracted a top-module [16]. A top-module is
used as in the PxO only a restricted query supporting
a CQ needs to be answered, rather than a query that
necessitates all entailments from a signature to be pre-
served. The following OBO or their parts were used in
PxO:
1. The Protein Ontology (PRO) [17] — Reuse
of Protein(PR:000000001) and proteolytic
cleavage product(PR:000018264) that are both
subclasses of PRO’s amino acid chain (PR:000
018263). In order to follow the PRO annotation
guidelines [18], the relationships participates
in; located in; and has function were
substituted with their Relationship Ontology
equivalents. The use of the PRO supports all the
CQ.
2. Relationship Ontology (RO) [19] — Where possi-
ble, PxO uses object properties from RO. For PxO,
this includes has_function, has_location,
participates_in and only_in_taxon.
3. the three Gene Ontology (GO) sub-ontologies [20] —
First, a class name extraction was performed based on
the three GO namespaces cellular component;
molecularfunction; andbiological process.
As an example of usage in the PxO, the GO
class peptidase activity (GO:0008233) was
used to define protease molecular function, while
proteolysis (GO:0006508) was used to describe
the biological process of peptide production. Use of
the GO supports CQ 1, 3 4 and 6.
4. Chemical Entities of Biological Interest Ontology
(ChEBI) [21] — Reuse of chemical entity
(CHEBI: 24431) that has as subclass molecular
entity(CHEBI: 23367). PRO’s amino acid chain
(PR:000018263) and amino acid were made
subclasses of ChEBI’s molecular entity(CHEBI:
23367). The twenty amino acids are also taken from
ChEBI. Some amino acids are interchangeable at
a certain CS position, for they may have identical
biochemical properties. This supports the answering
of CQ 5.
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5. Phenotypic Quality Ontology (PATO) [22] — Classes
from PATO were reused to describe the prop-
erties of the amino acids. Hence, classes such as
electric charge (PATO:0002193), polarity
(PATO:0002182) as well as their superclasses like
molecular quality (PATO:0002182) and
subclasses such as negative charge (PATO:
0002196) were extracted. The twenty amino acids
from ChEBI are classified taken PATO’s descendants
from molecular quality and side chain
structure, which is outside of PATO. This helps to
answer CQ 5.
6. the Sequence Ontology (SO) [23] — Cleavage
site regions and C- and N-terminus of polypep-
tide sequences were described using polypeptide
region (SO:0000839) to describe Cleavage site
region. Moreover, the key classes to link proteins
from Uniprot with gene names were described using
gene (SO:0000704) along with its subclass protein
coding gene (SO:0001217). Based on superking-
dom and subclasses, i.e. upper-levels of the UniPro-
tKB Taxonomy, the gene names are classified, and
thereby, obtaining a hierarchy with three levels. These
classes were used to support the CQ 1, 2, and 4.
7. The PRO proteins are organised based on taxon
organism, and therefore, new classes under the PRO
proteinclass were created according to the upper-
levels of the UniProtKB Taxonomy [24]. These classes
were used to support CQ 3.
8. GALEN ontology [25] — A medical ontology outside
of OBO, which can be downloaded from BioPortal
[26]. Reuse of the class KnowledgeStatus and the
relationship hasKnowledgeStatus to represent
observed or predicted proteolysis. To describe the
level of confidence associated with a predicted
proteolysis, the relationship hasConfidence
LevelStatus the class ConfidenceLevel
Status were also extracted. these classes were used
to support CQ 1.
PxO axioms and axiom patterns
Peptide and protein: A peptide, also known as
proteolytic cleavage productin PRO, is
described in the following way in PxO (all OWL frag-
ments are represented using Manchester OWL Syntax
[27]):
Class : ’ p r o t e o l y t i c c l e a v a g e product ’
SubClassOf :
’ amino ac i d chain ’ ,
’ output of ’ some p r o t e o l y s i s ,
’ d e r i v e s from ’ some p ro t e i n
Knowledge patterns are representations which capture
recurring structure within and across ontologies [28]. And
therefore, knowledge patterns (patterns for short) can
be seen as generalisations where entities are replaced
by variables [29]. The above pattern conteins two vari-
ables ?Peptide and ?Protein. When the pattern is instan-
ciated, the variables will be replaced with entities. For
example, for peptide with ID 1023927 the variable
?Protein will be replaced with the parent protein from
which the peptide is derived, which is PRO’s Collagen
alpha-1(I) chain (PR:P02452). It should be noted
that a pattern (a.k.a. axiom pattern) does not neces-
sarily coincide with the notion of ontology design
pattern (see [29]). A pattern can also represent a set
of OWL axioms. And thus an ontology’s class expres-
sions or definitions can be easily obtained instanciating
patterns.
The description of proteins in the PxO follows guide-
lines for the PRO [18] and it uses the RO object
properties ‘has function’ to relate a protein to
its GO molecular_function, ‘has location’ to
relate a protein to its location in a GO ‘cellular
component’ and ‘participates in’ to relate a
protein to the GO ‘biological process’ in
which it may participate. Proteins are thus described in
the PxO with the following axioms:
Class : p r o t e i n
SubClassOf :
’ amino ac i d chain ’ ,
’ l o c a t e d in ’ some ce l lu l a r_component ,
’ p a r t i c i p a t e s in ’ some b i o l o g i c a l _ p r o c e s s ,
’ has func t ion ’ some molecu l a r _ func t i on
The aim in PxO is to describe protein types taken
from Uniprot described by terms from the Gene Ontol-
ogy according to PRO guidelines. Given the PRO protein
Collagen alpha-1(I) chain (PR:P02452), the fol-
lowing two axioms are made by instanciating the above
pattern
Class : ’ Co l l agen alpha −1( I ) chain ’
SubClassOf :
’ l o c a t e d in ’ some ’ e x t r a c e l l u l a r reg ion ’ ,
’ l o c a t e d in ’ some ’ e x t r a c e l l u l a r space ’
UniProtKB/Swiss-Prot [30] contain more than one hun-
dred thousand protein records for metazoa (i.e. mul-
ticellular animals) that were reviewed, and manually
annotated. Some of these proteins have isoforms, i.e.
alternatives to the canonical sequence. The PxO is
released currently with the PxO metazoa that contains
139 720 OWL protein classes (UniProtKB SwissProt and
Isoform sequences), 4 591 OWL organism taxons, and
with 89 846 OWL gene classes. Each type of OWL Class
(protein, gene, and organism taxon) is generated using its
own axiom pattern.
Both proteins and peptides have N-terminus- and C-
terminus regions. Thus, axioms were introduced to refine
PRO’s amino acid chain:
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Class : ’ amino ac i d chain ’
SubClassOf :
’ mo lecu la r e n t i t y ’ ,
h a s _pa r t some ’C−terminus reg ion ’ ,
h a s _pa r t some ’N−terminus reg ion ’ ,
h a s _pa r t some po l ypep t i d e_ r eg i on ,
on l y_ in_ t axon some organism
Cleavage sites: On the one hand, a cleavage site (CS) is
part of a protein. On the other hand, a protein may have
one or more CS. Therefore, two patterns were created.
PxO is released currently with 16 273 OWL CS classes
for known cleavage sites, which are associated with 5 084
distinct protein classes.
Protease: An equivalence axiom allows any protein
with a GO annotation for peptidase activity(GO:
0008233) or one of it’s children to be recognised as a pro-
tease by Proteasix. The axioms for representing proteases
are as follows:
Class : P r o t e a s e
EquivalentTo :
p r o t e i n and ( ’ has func t ion ’
some ’ p e p t i d a s e a c t i v i t y ’ )
SubClassOf :
’ i npu t of ’ some p r o t e o l y s i s
In the same vein, it is straight-forward to define a
class such as exopeptidaseby using the GO anno-
tation for exopeptidase activity (GO:0008238).
Definitions for endopeptidase, aminopeptidase
and carboxypeptidase are easily made by exploiting
the GO’s catalytic activity hierarchy.
Proteolysis: Taking the GO’s proteolysis, it is feasi-
ble to create additional axioms to describe the biological
process that has input participants of a substrate protein,
a protease and has output participants proteolytic
cleavage fragment
Class : p r o t e o l y s i s
SubClassOf :
’ p r o t e i n metabo l i c process ’ ,
’ has input ’ some Protease ,
’ has output ’ some ’ p r o t e o l y t i c
c l e a v a g e product ’ ,
’ has input ’ some ( p r o t e i n and
( h a s_pa r t some ’ C leavage s i t e reg ion ’ ) )
In the PxO there is a clear distinction between:
a) observations of protease/CS combinations extracted
from the literature (e.g. CutDB [8]); and b) predic-
tion of cleavage based on protease’s cleavage site speci-
ficity from MEROPS [9] or exopeptidase’s cleavage site
annotation assertions with the catalytic activity from
BRENDA [10], which captures how likely it is for an
amino acid to be present or absent in a certain posi-
tion close to the CS. To represent this dichotomy,
two classes were introduced: observed proteolysis
and predicted proteolysis. To create their class
definitions, the status of the proteolysis is indicated.
Observed proteolysis is defined as:
Class : ’ Observed p r o t e o l y s i s ’
EquivalentTo :
p r o t e o l y s i s and ( hasKnowledgeSta tus
some ’ Observed s t a t u s ’ )
In the PxO there are 20 229 observed proteo
lysis and 329 predicted proteolysis created
from two patterns.
Annotation assertionsprovide the means to
associate aditional information with an entity, like an
exact synonym (oboInOwl:hasExactSynonym), a database
cross reference (oboInOwl:hasDbXref ), or a definition
(IAO:0000115). When a protein taken from the UniPro-
tKB has a MEROPS specificity matrix, annotation asser-
tion axioms are used in PxO to represent this data.
However, the probability for a protease to cleave a protein
substrate is calculated outside of the PxO, although using
the annotation properties and values in the PxO.
PxO in use
There are two methods to find the protease classes in the
PxO: 1) use an automated reasoner like ELK [31] to infer
which proteins are proteases (see the Protease defined
class in the previous section); or 2) use the SPARQL 1.1
query language [32] to create a SELECT query (Q0) that
retrieves the OWL protein classes with a GO assertion
for peptidase activity (GO:0008233) or any of it’s
children. Likewise, using DL queries with ELK or SPARQL
SELECT queries, the proteins that are endopeptidase,
aminopeptidase or carboxypeptidase can be
obtained.
The essence of the Proteasix algorithmis given
below, which exploits the PxO ontology, and uses the
competency questions CQ. The algorithm assumes that
protease cleavage of substrate proteins is directed by short
amino acid motifs, from two to eight amino acids of
the type (Pn . . . )P1 - P1’(. . . Pn’), with the scissile bond
between P1 and P1’ residues [5]. Residues towards the
N-terminus of the substrate are on the non-prime side
and numbered as P1 P2 P3 P4 and so on; while residues
towards the C-terminus are on the prime side and num-
bered as P1’ P2’ P3’ P4’ and so on [33].
STEP 1: User input — For each peptide, the end-user
provides: a) the peptide identifier; b) the UniProt Acces-
sion Number (AC) or identifier (ID) of the parent protein
from which the peptide is derived; c) the start amino acid
position with respect to the parent protein’s sequence, i.e.
P1’ of the N-terminus CS; and d) the end amino acid posi-
tion with respect to the parent protein’s sequence, i.e. P1
of the C-terminus CS.
STEP 2: Reconstruct N- and C-terminus CS — Each
OWL protein class created from the UniProtKB (Swiss-
Prot/TrEMBL) has among others the following anno-
tation properties: oboInOwl:id for AC; oboInOwl:
hasAlternativeId for ID; and PxO:hasSequence
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where the amino acid sequence (sequence for short) of the
protein is stored. SPARQL query CQ2-2 in the Additional
file 1 exemplifies how to obtain the amino acid sequence
for protein P02768 (PR:P02768). Outside of PxO, and
using the protein sequence, the peptide sequence for an
input peptide is extracted, and the N- and C-terminus are
reconstructed, i.e. eight amino acids or fewer if close to
the beginning or end of the protein’s sequence. The out-
put of this step is the creation for each input peptide of an
OWL peptide class along with an OWL N-terminus class
and an OWL C-terminus class.
STEP 3: Observed cleavage — Using the class expres-
sion polypeptide region SubClassOf ’part
of’ some ’amino acid chain’OWL CS classes
and OWL protein classes are linked, and therefore, this
class expression represents that a CS is part of a pro-
tein. An OWL CS class also has annotation properties
for storing the CS sequence and the P1 and P1’ values.
SPARQL query CQ2-1 in the Additional file 1 illustrates
how to retrieve for protein P02768 (PR:P02768) the
observed CS regions where the P1’ value is 25. To make
the retrieval process more efficient, firstly, for each
peptide, the sequence of its corresponding OWL N-
terminus class and OWL C-terminus class are matched
against the OWL CS class sequence. If successful, a
more detailed match is triggered. A successful outcome
of this step is an instantiation of the axiom pattern
?peptide SubClassOf ’output of’ some
(?proteolysis and (hasKnowledgeStatus
some ’Observed status’)).
STEP 4: Predicted cleavage — For the OWL N-
terminus and C-terminus classes with sequences that
remain unmatched after the previous step, a protein cleav-
age prediction is attempted. SPARQL query CQ4 in the
additional file can be generalised by replacing the PRO’s
protease P08253 (PR:P08253) for a parameter ?C, and
thus, the results of the query will be the set of proteases
for which prediction can be undertaken by exploiting the
MEROPS cleavage site specificity matrix. The probability
calculations are outside of PxO. Firstly, the probability of
cleavage is estimated from the protease’s MEROPS speci-
ficity matrix [9] using a log-likelihood. If the probability
is above the 99th percentile of the population distribution
of all possible sequences, then the sequence is taken as
statistically matched. A confidence level is then assigned
to the matching, using levels from a simulation distribu-
tion of thematching step. Secondly, for the sequence’s that
obtained a low/medium confidence level prediction or still
have no prediction, BRENDA [10] exopeptidase’s catalytic
information is used and a second prediction is attempted,
assuming that after endopeptidase cleavage, and exopep-
tidase cuts the free extremity (i.e. C- or N- terminus
CS). A successful outcome of this step is an instantia-
tion of the axiom pattern ?peptide SubClassOf ‘output
of ’ some (?proteolysis and (hasKnowledgeStatus some ‘Pre-
dicted status’)).
Further validation of the observed and predicted prote-
olysis (step 3 and 4) is accomplished by checking in PxO
that: a) If the source organism for the protease and the
substrate are the same; and b) if both the protease and the
substrate are co-located.
Positive example: In the additional file, there is
an SPARQL SELECT query (CQ3-2) that investi-
gates whether the two above-mentioned conditions are
met for PRO’s substrate Serum albumin (PR:P02768)
and PRO’s protease 72 kDa type IV collagenase
(PR:P08253). The query indicates that both protease
and substrate protein may come from the same taxon
Homo sapiens (NCBI:9606) and may have the fol-
lowing common co-locations: nucleus(GO:0005634);
extracellular region(GO:0005576);
extracellular space(GO:0005615). This is a pos-
itive corroboration of co-location. Indeed, there is evi-
dence that the cleavage is observed.
Negative example: Reusing the SPARQL SELECT
query (CQ3-2) with different protease Neutrophil
elastase(PR:P08246) and substrate protein
ATP-binding cassette sub-family A
member 6(PR:Q8N139). The query indicates that both
protease and substrate protein may come from the
same taxon Homo sapiens (NCBI:9606), however
no common co-locations are found. This reinforces the
low confidence level status assigned to the prediction
obtained.
Discussion
The first version of Proteasix was agnostic as to species,
location and function of the proteases and their sub-
strate proteins. The PxO allows knowledge of the domain
to be added to the Proteasix algorithm. The PxO allows
Proteasix to add semantics to its data such that the algo-
rithm can check proteases for their function and both
protease and substrate for species and location, as well as
making the data reliably queriable. The aim here is two-
fold: first, separating operational knowledge from domain
knowledge; this will enable update and expansion of the
knowledge component with relative ease. Second, the aim
is to allow Proteasix and human users to check the valid-
ity of Proteasix results. These results may not be improved
due to the use of PxO, but may be interpreted with more
confidence.
The bulk of the PxO has been developed through re-
use of other ontologies and these were ontologies mainly
from the OBO Consortium. In doing so we have commit-
ted to the ontological viewpoint of those ontologies. We
have not substantially changed those ontologies, except to
extend, as it makes interoperability with other OBO based
applications harder, as well as update and maintenance
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more difficult. This commitment does, however, come at
a potential cost. Like any commitment, making one com-
mitment excludes others. The OBO, like most ontologies,
are not without their controversies. The GO, in particular,
has long had its critics both on ontological and logi-
cal grounds [34, 35] There is debate about whether the
‘molecular function’ in the GO is ontologically a function
or a finer grained process than theGO’s ‘biological process
[34]. The GO has also been criticised for inconsistency in
its modelling and lack of constraints that allow automated
reasoning to be applied more effectively [35, 36]. In the
PxO we have taken these aspects into account with Pro-
teasix’s application needs and resources, and have decided
that commiting to the OBO is an appropriate choice; this
decision will be kept under review.
There is much further work to be done in the PxO. Cur-
rently, we only incorporate cannonical and isoform infor-
mation from the UniProtKB, which also contains much
information about sequence variants. Inclusion of this
may improve the analysis done by Proteasix. The Gene
Ontology annotations used in describing proteins can be
accompanied with evidence codes [13], and therefore, tak-
ing into account with what confidence annotations are
made may also improve the utility of the PxO in Pro-
teasix. Another line of work is to map the cleavage to
the peptidase family instead of mapping the cleavage to
an individual enzyme. A protein is typically represented
as having many functions, in many locations and being
involved in many biological processes. At present which
functions, in which process and in which location is not
represented. As this kind of representation emerges it will
be adopted in PxO and may contribute to the accuracy of
predictions made in Proteasix.
The PxO has its limitations in addition to those indi-
cated by the future work. The PxO, like most ontologies,
is limited by the state of knowledge in its domain, which
for PxO is large. That confirmatory information on a pro-
tease protein interaction is not found does not mean it
cannot occur. The knowledge in the literature is much
greater than that in ontological form. Nevertheless, if PxO
can help give confidence to Proteasix’s predictions then it
is a help.
A further limitation comes in the ability to predict
cleaveage sites in Proteasix. Proteases exhibit varying
binding affinities for amino-acid sequences, ranging from
strict restriction to one or few critical amino-acids in
given positions, to generic binding with little discrim-
ination between different amino acids. The MEROPS
database [9] lists such information. When available,
MEROPS specificity weight matrices were added to PxO.
The MEROPS specificity matrix shows how frequently
each amino acid occurred at each position in the cleavage
site. Matrices were further transformed into Probabil-
ity Matrices, by dividing the number of occurrences for
each amino acid in each position with the total num-
ber of observations. It has been acknowledged that to be
able to study peptidase specificity and make predictions
about where in a protein cleavage might occur, at least 40
cleavages in substrates are required [33] and/or a mini-
mal 10 times enrichment for one amino acid should be
observed in at least one position of the CS. Hence, the
availability of MEROPS peptidase specificity data is a hard
limitation of the current approach, which is a limitation
inherent to experimental science. However, the predic-
tions of Proteasix will improve as the body of evidence
increases.
This research work was done for the sysVASC project,
and so the emphasis is on Metazoa, where the organisms
human, mouse, and rat are the main focus. Despite the
large amount of work still to do in the PxO, the PxO nev-
ertheless is a rich ontology supporting peptide analysis
that has been enabled by re-using the ontologies pro-
duced by the OBO Consortium; the PxO has partitioned
these ontologies based on the task they need to support
and enriched them axiomatically on the same basis. As a
result Proteasix can better support the prediction of pro-
teases implicated in the production of peptides and the
consequent elucidation of biological mechanisms.
Additional file
Additional file 1: PxO Metazoa ontology: Ontology metrics; ELK reasoner
times; and SPARQL queries execution times. (PDF 141 kb)
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